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Two genes code for calcitonin gene-related peptides (CGRPs). One expresses by tissue-specific alternate splicing calcitonin and CGRP I mRNAs, 
the other CGRP II mRNA. Calcitonin is the marker of sporadic or hereditary human medullary thyroid carcinoma (MTC). CGRP II expression 
is not well established in normal or tumoral thyroid. After amplification by polymerase chain reaction, CGRP I and II mRNAs were detected 
in six cases of MTC associated with other endocrine neoplasia (MEN IIa) and in two cases of isolated MTC, CGRP I was detected in all non-C 
cell tumoral thyroids (6 samples), CGRP II was barely detectable in three out of six cases. CGRP II could be a specific tumoral marker of MTC. 
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1. INTRODUCTION 
Medullary thyroid carcinoma (MTC), though a rare 
tumor (O.~~o), occurs in familial and sporadic forms. 
It is a clinically heterogeneous disease, either isolated 
(MTC ‘only’) or associated with other endocrine 
neoplasia (multiple endocrine neoplasia) in the clinical 
syndromes of MEN IIa (MTC and pheochromocytoma, 
and/or p~athyroid adenoma) and MEN IIb (MTC and 
dysmorphic habitus). 
Calcitonin (CT) is the biological marker of MTC [l]. 
Measurement of basal and stimulated levels of the hor- 
mone represents the basis of the diagnosis, prognosis 
and detection of high risk individuals in the hereditary 
form of the disease [Z]. However, the CT gene (CALC 
I) expresses a neuropeptide ‘calcitonin gene related pep- 
tide’ (CGRP) in addition to CT. Alternate splicing of 
the transcript of the CTKGRP gene [3] leads to the 
formation of two specific mRNAs having a common 
5 ‘-terminal region and 3 ‘-regions specific for CT or 
CGRP. Expression of these peptides is tissue specific, 
as CT is preferentially expressed in thyroid and CGRP 
in the central and peripheral nervous system [4]. A se- 
cond CT-related gene (CALC II) codes for CGRP II but 
is a pseudogene for CT. 
Expression of CT-related genes in normal and 
tumoral thyroid tissues is not well studied: CT is 
detected in all thyroid tissues whereas it is not known if 
CGRP I and II are co-expressed or not in tumoral 
tissues [5,6]. In the case of isolated MTC, CGRP I has 
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been detected by radioimmunoassay [7]. In non- 
tumoral thyroid tissues CGRP I and CGRP II 
messengers were not detected by Northern blot analyses 
[8] whereas both peptides were detected by radioim- 
munoassay (91. 
In studies of the expression of CTKGRP gene in 
MTC patients we failed to detect CGRP mRNAs in 
samples of non-tumoral thyroid tissues using blot or 
Northern analysis. We have therefore used the 
polymerase chain reaction to amplify specifically 
transcripts of CALC I and CALC II genes. In all 
samples of medullary thyroid tumors studied CT, 
CGRP I and CGRP II were detected by ethidium 
bromide staining. In normal tissues, only CT was 
visualized by ethidium bromide fluorescence, 
hybridization of the amplified RNAs transferred to a 
nylon membrane with specific probe was positive for 
CGRP I in all control samples and barely detectable for 
CGRP II in 3 out of 6 control tissues. These results im- 
ply that expression of CGRP II is extremely low in non- 
tumoral C cells thyroid tissues and the tumorogenicity 
is apparently always accompanied by an increased pro- 
duction of CGRP II. 
2. MATERIALS AND METHODS 
2.1. Tissue samples and isolation of RNA 
Medullary thyroid carcinomas were obtained from patients suffer- 
ing from MEN Ha (5 familial and 1 apparently sporadic cases) and 
sporadic MTC ‘only’ (2 cases). Control tissues were obtained from 
non-tumoral thyroids (5 cases), and from an oxyphil cell carcinoma 
presenting an important C cell hyperplasia. Samples were rapidly 
frozen in liquid nitrogen. Total RNA was extracted by 
pheno~/chioroform, purified by LiCl precipitation [IO] and quan- 
tified by absorbance at 260 nm. 
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(CALC II) I.~ .~_ 
2.2. Ampltfifation method 
2.2.1 Reverse tra~er~ptas~ reaffirm 
The first cDNA strand was synthesized from 10 pg of denaturated 
total RNA, by extension of a 3 ‘-poiy(dT) primer (10 pmol), with 200 
units of MoMuLV reverse transcriptase (BRL) in a final volume of 20 
pl containing 1 x reverse transcriptase buffer (BRL), 20 units of 
RNase inhibitor (Boehringer) and 1 mM of each dNTP. 
The reaction was performed at 37°C for 40 min, then stopped on 
ice. 
2.2.2. Polymerase chain reaction (PCR) protocol 
80 pl x PCR buffer (Cetus) containing 20 pmol each of upstream 
and downstream specific primers and 2.5 units of AmpliTaq DNA 
polymerase (Cetus) were added to 20 pl reverse transcriptase reaction 
mixture. 
Amplification was performed on a programmable heater (Perkin 
Elmer) for 25 cycles. The reaction began with a denaturation step, 
94°C for 2 mn followed by 25 cycles of denaturation at 94°C for 1 
min, annealing at 55°C for 1 min (60°C for CGRP II amplification) 
and elongation at 72°C for 2 min (6 min for the last cycle). 
2.3. Anaiysis of results 
After agarose gel electrophoresis, PCR products were quantified by 
two methods. 
(i) The gel, containing ethidium bromide, was photographed under 
UV light using positive/negative instant pack film (Polaroid 665) and 
the negative analysed by densitometry using a densitometer module 
(Transidyne General Corp.). 
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(ii) The DNA was biotted on Gene Screen membrane (New England 
Nuclear, Boston, MA) and hybridized with specific probes using an 
already-described protocol [15]. The probes corresponded respective- 
ly to 116 base pairs of CALC 1 exon 4 coding for CT and 126 base 
pairs of CALC I exon 5 coding for CGRP I. They were labeled by ran- 
dom primer reaction [16] using [cu-32P]dCTP to a specific activity of 
2-5 x 10’ cpm/pg DNA. 
3. RESULTS 
3.1. CT mRNA 
Ethidium bromide staining of agarose gel elec- 
trophoresis of amplified products using CT mRNA 
specific primers revealed a single, strongly stained band 
in all six MEN IIa patients corresponding to the ex- 
pected size (392 bp) (Fig. 1: lanes l-6) and in both cases 
of isolated MTC (data not shown). No such signal was 
observed in non-MTC samples with the exception of a 
C cell hyperplastic sample (Fig. 1: lane 7) in which a 
moderately stained band was observed. After transfer 
of the gels to Gene Screen membrane and hybridization 
to a specific CT probe a faint band of the same size was 
observed in the autoradiographies of all the control 
samples. Fig. 2 shows the autoradiography of three 
control cases and an MTC case. 
Fig. 1. Agarose gel analysis of PCR products. Total RNA extracted 
from the tumor was reverse transcribed and amplified with specific 
CT mRNA primers. One-fifth of the reaction was submitted to gel 
electrophoresis. (Lanes l-6) Tumoral tissues; (lane 7) control thyroid. 
Molecular weight markers (M) consisting of the 2.17 kb, 1.76 kb, 1.23 
kb, 1.03 kb, 0.65 kb, 0.51 kb, 0.45 kb, 0.39 kb, 0.29 kb, 0.22 kb and 
0.15 kb BgiI and Hinfl restriction fragments of pBR 328. The I .2% 
agarose gel contained 0.5 @g/ml ethidium bromide. 
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Fig. 2. Autoradiogram after hybridization, with CT-specific probe, of 
a Southern blot with PCR products amplified with specific CT mRNA 
primers. (Lanes 1-3) Control tissues, each sample represents l/4 of 
the starting material; (lane 4) MTC tissue, 1140 of the PCR reaction 
was analysed. 
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Fig. 3. Autoradiogram after hybridization with CGRP probe of a 
Southern blot of PCR products amplified with specific CGRP I 
mRNA primers. (Lanes l-3) MTC tissues, l/40 of the reaction was 
analysed; (lanes 4-7) control tissues, l/4 of the reaction was analysed. 
1234567M 
Fig. 4. Agarose gel analysis of PCR products. Reverse transcribed 
mRNAs were amplified with specific CGRP II mRNA primers. One- 
fourth of the reaction was submitted to gel electrophoresis. (Lanes 
l-6) MTC tissues; (lane 7) control tissue. Molecular weight markers 
(M) = the same as in Fig. 1. 
3.2. CGRPImRNA 
Using primers specific to CGRP I mRNA we detected 
PCR products in the eight cases of MTC by ethidium 
bromide fluorescence (data not shown). After transfer 
and hybridization, we detected CGRP I mRNA in all 
control cases. Fig. 3 shows the autoradiography of 
three MTC cases and four control cases. 
3.3. CGRPIImRNA 
A specific band was observed in the eight cases of 
MTC. Fig. 4 shows PCR products using primers 
specific to CGRP II mRNA of six cases of MEN IIa 
visualized with ethidium bromide. CGRP II mRNA 
after Southern blot and hybridization was detectable 
(OD ~0.01) in three out of six control samples. 
The results of PCR reaction are summarized in Table 
II. 
The CT/CGRP I ratio was not statistically different 
between the various groups, using parametric and non- 
parametric test (Anova P = 0.74; Kruskal-Wallis P = 
0.93) in contrast the CGRP II/CGRP I ratio was 
significantly different between the various groups 
(Anova P = 0.0002; Kruskal-Wallis P = 0.008) being 
maximal in isolated MTC and minimal in control 
tissues. 
4. DISCUSSION 
Though the structure and sequence of the CT-related 
genes are well established in man, modifications in the 
expression of these genes in the course of MTC are not 
well documented. This is probably due to the rareness 
of the disease (1 out of 25 000 subjects) and to the ex- 
istence of multiple clinical forms. We have chosen to 
study MEN IIa, the most frequent familial form of the 
disease and in two cases of isolated sporadic MTC. 
In order to amplify specifically the mature form of 
the mRNAs we used oligo(dT) as a primer for the 
reverse transcriptase reaction and specific primers for 
the Taq polymerase in the terminal 5’- and 3’-regions 
of the cDNA. The length of the transcripts we amplified 
was the same as that of the respective mRNAs. We 
detected CT transcripts in all control samples studied, 
thus confirming the presence of a C cell population. 
Our results establish the presence of mature CGRP I 
and CGRP II mRNA in all medullary carcinoma of the 
thyroid. We detected CGRP I transcripts in all control 
tissues studied, demonstrating for the first time that in 
these tissues, the expression of the CT/CGRP gene 
leads to the production of specific mRNAs coding for 
CGRP I. 
The CALC II gene expression is more complex, as ex- 
tremely low levels were detected by hybridization, after 
amplification, in only 3 out of 6 samples from non- 
Table II 
Quantification of CT, CGRP I and II mRNA, after PCR amplification of total RNA extracted from control and tumoral thyroid human tissues 
Men lla Isolated MTC Control tissues 
CT 900.3 + 97.4 (6) 505 * 120 (2) 17.8 & 11.2 (6) 
CGRP I 183.2 f 24.5 (6) 102 f 51 (2) 2 & 0.6 (6) 
CGRP II 245.5 f 46.8 (6) 246 * 66 (2) 0.6 + 0.4 (6) 
CT/CGRP I 5.9 + 1.7 (6) 7.4 + 4.9 (2) 8.9 f 3.3 (6) 
CGRP ll/CGRP I 1.4 k 0.2 (6) 3 + 0.9 (2) 0.2 f 0.1 (6) 
Values reported are means + SE of relative DNA quantity (arbitrary units), number in parentheses indicates the number of samples. 
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tumoral thyroid. This low level of CGRP II gene ex- 
pression in these three samples could simply reflect a 
mild C cell hyperplasia secondary to disturbances in 
follicular cell metabolism. This hypothesis is in part 
supported by the detection of higher levels of CGRP II 
mRNA in one oxyphil thyroid cancer, in which we 
authenticated C cell hyperplasia by specific staining of 
the C cells (data not shown). 
Analysis of the ratios of CALC I and II genes expres- 
sion between tumoral and non-tumoral tissues is of par- 
ticular interest. For CT and CGRP I mRNAs the ratios 
are statistically not different indicating that the critical- 
ly regulated step (splice choice) could be independent of 
the level of CT/CGRP I gene expression in human 
tumoral and non-tumoral C cells and agree with the 
results in rat MTC (171. We have also compared CALC 
I and CALC II genes expression, the ratios of CGRP 
II/CGRP I between clinical groups are different, in- 
dicating that the regulation of the expression of these 
related genes could be different in normal and 
neoplastic C cells. Similar results were observed in 
cultured cells of murine MTC in response to dex- 
amethasone treatment [ 181, 
In conclusion, CT and CGRP I are both produced by 
normal C cells and their increase in malignant umors is 
probably a reflection of an increase in the number of C 
cells. Furthermore the ratio of CT mRNA to CGRP I 
mRNA in our samples is in favour of the maintenance 
of normal splicing mechanisms in the tumoral cells we 
have studied. On the other hand, the increased levels of 
CGRP II mRNA expression in the tumoral samples 
could be due to an activation of its gene during C cell 
proliferation. If this is the case, CGRP II should be 
considered as a second tumoral marker in MTC. 
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